Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Orfiril Long vs Ergenyl Chrono in Healthy Volunteers
NCT06214130Phase 1Completed
- Sponsor
- Desitin Arzneimittel
- Start
- Sep 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Orfiril Long in epilepsy (2 arms), sponsored by Desitin Arzneimittel. Primary endpoints: Area under the curve during steady state at Day 6 and Maximal plasma concentration during steady state at Day 6. Started Sep 2023; status: completed.
02
Drugs
Orfiril Long
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT06214130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06214130.